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Protein kinases play important roles in regulating signal transduction in eukaryotic cells. Due to evolutionary
conserved binding sites in the catalytic domain of the kinases, most inhibitors that target these sites promiscuously
inhibit multiple kinases. Quantitative analysis can reveal complex and unexpected interactions between protein
kinases and kinase inhibitors, providing opportunities for identifying multi-targeted inhibitors of specific diverse
kinases for drug repurposing and development. We have developed K-Map—a novel and user-friendly web-based
program that systematically connects a set of query kinases to kinase inhibitors based on quantitative profiles of
the kinase inhibitor activities. Users can use K-Map to find kinase inhibitors for a set of query kinases (obtained from
high-throughput ‘omics’ experiments) or to reveal new interactions between kinases and kinase inhibitors for
rational drug combination studies.
Availability and implementation: K-Map has been implemented in python scripting language and the website is
freely available at: http://tanlab.ucdenver.edu/kMap.Introduction
Protein kinases represent one of the largest ‘druggable’
and well-studied families in the human genome [1]. This
class of proteins (kinome) plays a key role as regulators
and transducers of signaling in eukaryotic cells. There is
an estimated >500 members of the human kinome which
can be classified into seven different kinase families based
on their conserved catalytic domain sequences [2]. Kinases
are relatively easy to target with small molecules and have
been extensively studied at the biochemical, structural,
and physiological levels. In cancer cells, some kinases
are mutated and acquire oncogenic properties to drive
tumorgenesis. Small molecules that inhibit these oncogenic
kinases can effectively kill cancer cells, as demonstrated
by the success story of imatinib (Gleevec®, Novartis, Basel,
Switzerland) in inhibiting the activity of BCR-ABL in
chronic myelogenous leukemia [3]. Imatinib also inhibits
KIT and PDGFRA, which are commonly dysregulated in
gastrointestinal stromal tumors [4]. The imatinib example
illustrates that small-molecule kinase inhibitors interact
with multiple protein kinase family members (BCR-ABL,* Correspondence: aikchoon.tan@ucdenver.edu
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reproduction in any medium, provided the orKIT, PDGFRA), and understanding these complex interac-
tions between kinases and inhibitors could be useful for
drug repurposing and development. These complex inter-
actions could only be revealed by systematic interrogation
of the small molecules across a large panel of kinases using
quantitative assays (kinase activity profiles). Here, we have
developed K-Map—a novel and user-friendly web-based
program that systematically connects a set of query kinases
to kinase inhibitors based on quantitative profiles of the
kinase inhibitor activities. K-Map is motivated by the
‘connectivity map’ concept [5] where gene expression
changes could be used as the ‘universal language’ to
connect between biological systems, genes, and drugs.
Instead of gene expression signatures, we used the kinase
activity profiles as the ‘language’ for connecting kinases and
small molecules in K-Map to reveal the complex interac-
tions of kinases and inhibitors.
K-Map methods and features
Quantitative kinase inhibitor selectivity data sources
Two recently published comprehensive analyses of kinase
inhibitor selectivity [6,7] were used to construct the K-Map
reference database (kinase activity profiles). The first
study systematically interrogates 178 commercially available
inhibitors against a panel of 300 protein kinases using a
radiometric phospho-transfer method to assess the percent. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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hibitor selectivity and potency of 72 inhibitors across 442
kinases using direct binding affinities between inhibitors
and kinases (Kd) [7]. These kinase activity profiles were
converted into rank-ordered lists according to their
inhibitions and potencies against the kinases and used
as the K-Map reference profiles for matching query kinases.
For each study, the kinase activity profiles for individual
drugs were converted into rank-ordered lists according to
their inhibitions and potencies against the kinases. As a
result, we generated two K-Map reference databases from
these two studies: one for IC50 and the other one are
for Kd. Both databases will be used to connect the
query kinases and return the drugs in K-Map.
Pattern matching strategy
We implemented the K-Map pattern matching strategy
based on the Kolmogorov-Smirnov (KS) statistics. The
KS test is a nonparametric, rank-based pattern matching
approach implemented in the connectivity map [5]. The
query is a list of kinases, and the goal of the algorithm is
to correlate kinase inhibitor that enriches the same kinases
based on kinase inhibition profiles. For every inhibitor in
the reference database, the KS statistic is computed and a
connectivity score is defined.
Similar to the connectivity map approach [5], to com-
pute the connectivity score, let N be the number of
kinases in the reference database and M be the number of
query kinases. For every drug in the reference database,
we can compute the rank-ordered list R for all kinases
(1, 2, …, N) based on the drug inhibitions and potencies
against the kinases. For a list of query kinases of j, where
j = 1, 2, …, M, compute the following two values for






















Let KSi be the KS score for drug i,
KSi ¼ a; if a > b;
−b; if b > a:

Finally, to compute the connectivity score (Si) for drug i









; if KSi < 0:
8><
>:The connectivity score (Si) for every drug is reported
as the ‘Score’ in the results page. A positive score represents
that the inhibitor has a similar rank order as the query
kinases, indicating that the inhibitor is more specific in
inhibiting the query kinases. A negative score represents
that the inhibitor has a reverse rank order as the query,
hence not specific in inhibiting the query kinases. Connect-
ivity scores for each inhibitor were normalized to yield a
score ranging 0 to 1, and inhibitors were ranked based on
this normalized score. We also computed the running sum
of the connectivity score for each inhibitor. The maximum
value of the running sum is equivalent to the connectivity
score of each inhibitor. Since the query kinases are unitless,
K-Map can be applied to any technology platform.
Computing the permutation p value
To estimate the p value for each drug i, we perform a
permutation test by randomly selecting the number of
M instances from the rank-ordered drug i kinase profiles.
Let t = 1, 2, …, T trials; the same procedure as computing
the KSi for drug i is performed T times and is denoted as
KSit . Let KS
i
0 denote the actual KS
i for drug i. Count the
number of times f where
KSit
 ≥ KSi0  	Tt¼1
is true. The frequency of this event (f/T) is estimated as a
(two-sided) p value. This procedure is similar to the im-
plementation of permutation test by the connectivity map
[5]. The p value reported in the results page of K-Map is
computed by 500 permutations.
Query features
K-Map implements three query functions: users can (1)
directly enter query kinases in the query text box or upload
a list of query kinases (Figure 1 (A)) in the K-Map tab, (2)
select kinases from the kinase family (Figure 1 (B)) in the
K-Map (by family) tab, or (3) query a set of kinases involved
in certain biological processes according to Gene Ontology
(Figure 1 (C)) in the K-Map (by GO) tab. Users also need
to define which database they would like their query
kinases to connect with (IC50 or Kd). All inhibitors
available in the K-Map could be browsed under the
Drug Info tab (Figure 1 (D)). Under the Download tab,
users can search and download kinase-inhibitor rela-
tionships. The Help tab provides user guide to query
and navigate the K-Map. The user manual for K-Map is
available at http://tanlab.ucdenver.edu/kMap.
Connectivity results and linking features
The output of K-Map is a rank-ordered list of inhibitors
based on the normalized connectivity scores, accompanied
by p values and running sum plots. The 2D drug structure
is viewable by scrolling through the drug name. Kinase
Figure 1 Query and results of the K-Map. Left, query features. K-Map could be queried by: (A) direct input or directly uploading a list of
kinases in the K-Map tab, (B) by selecting kinases from the kinase family, or (C) querying by Gene Ontology Biological Processes. All drug
information is available in the Drug Info tab (D) and could be downloaded in the Download tab. Right, connectivity results. Query kinases were
connected to the inhibitors and sorted by normalized connectivity scores. Link-out features include PubMed, PubChem, ChEMBL, and
ChemSpider for drug sources and information. K-Map also provides links to pathway, biomarker, and clinical trial information for each drug via
KEGG, GDSC, and ClinicalTrials.gov databases, respectively.
Figure 2 Query results for MET using Kd database. These four compounds were returned with connectivity score >0.9, indicating that these
compounds were highly specific in inhibiting MET. SGX-523 is ranked #1 and is a specific MET inhibitor, with Kd = 0.0019 μM as illustrated in the
kinase family tree. PHA-665752 is ranked #2 with Kd = 0.0027 μM against MET. These two compounds (SGX-523 and PHA-665752) were preclinical
compounds and have not moved into clinical trials. Forentinib is an FDA-approved drug that inhibits MET and KDR (Kd = 0.014 μM against MET)
and is ranked #3; however, the p value is high (p = 0.801). Crizotinib is also an FDA-approved drug that inhibits ALK, and this compound has
Kd = 0.021 μM against MET (p value = 0.004). Crizotinib was validated in in vitro experiments and showed synergistic effects when combined with
Nutlin-3 in p53wild-type cancer cell lines [13].
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erated under KinaseTree column where the red circles indi-
cate degrees of inhibition. Linking features are available for
data source of the kinase inhibition assay (via PubMed) and
three major chemical databases (PubChem [8], ChEMBL
[9], and ChemSpider (www.chemspider.com)). Additional
links to drug pathway and drug biomarkers are available
through the Kyoto Encyclopedia of Genes and Genomes
(KEGG) [10] and Genomics of Drug Sensitivity in Cancer
(GDSC) [11] databases, respectively. K-Map also provides
link-out to ClinicalTrials.gov for ongoing or completed
clinical trials of these inhibitors in various diseases. We
plan to update the K-Map database every quarter to keep
up with the new data and link-out information.
Implementation
K-Map is implemented in python (v2.6) and CGI script.
The kinase family tree map and 2D drug structure are
generated by the E.T.E. software (v2.0) and Open Babel
(v2.3.1) [12], respectively. The K-Map website is freely
available at: http://tanlab.ucdenver.edu/kMap.
K-Map application: case study
We have recently performed a genome-wide functional
genetic screen to identify synthetic lethality genes for
Nutlin-3 (p53 inhibitor) in p53 wild-type cancer cell
lines [13]. From this screening, we identified MET as a
synthetic lethal gene with Nutlin-3 in killing cancer
cell. By querying MET in the K-Map using Kd database
(Figure 1 (A)), four compounds were returned with con-
nectivity score >0.9 (Figure 1,right side). All four com-
pounds are specific in inhibiting MET with Kd ≤ 0.025 μM
(Figure 2). Interestingly, crizotinib, a recently FDA-approved
ALK inhibitor is ranked #4 (p value = 0.004). As we dem-
onstrated, treating p53 wild-type cancer cells with Nutlin-3
and crizotinib inhibits proliferation and enhances cell killing
in in vitro experiments [13]. This supports the finding that
the K-Map could reveal new inhibition of kinase inhibitor
(Figure 1, kinase family tree indicates that crizotinib shows
the highest selectivity in inhibiting ALK andMET).
Summary
K-Map is a novel and user-friendly web-based tool for
connecting kinases with drugs based on quantitative pro-
files of the kinase inhibitor activities. Many kinase inhibitors
could promiscuously inhibit multiple kinases due to con-
served sequence similarity among kinase family members;
we have exploited these complex and unexpected interac-
tions between kinases and inhibitors as opportunities for
drug repurposing and development. Users can use
K-Map to search kinase inhibitors for a set of query kinases
(obtained from high-throughput ‘omics’ experiments) or to
reveal new interactions between kinases and kinase inhibi-
tors for rational combination studies. In the future, we planto extend K-Map by including more kinase inhibitor pro-
files. In summary, we believe that K-Map will be a valuable
bioinformatics tool in connecting altered/mutated genes
identified by next-generation sequencing with therapeutics,
accelerating the process of personalized medicine.
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